Cardiovascular Disease

Global CVD Almanac

JACC released a special “almanac-style” issue highlighting the growing burden of cardiovascular disease worldwide. 

The Global Burden of Disease, Injuries, and Risk Factors study (GBD) is the world’s largest effort to track population cardiovascular health, recording global, regional, and national trends in mortality and disability since 1990. 

The analysis found that CVD remains the leading cause of death worldwide, responsible for 20M deaths and 400M disability-adjusted life-years lost in 2021. Here are the ACC’s main 2021 takeaways:

  • Ischemic heart disease was the leading cause of CV death, accounting for 9.4M deaths.
  • High systolic BP remained the leading modifiable risk factor for CV deaths, accounting for 10.8M. 
  • Dietary risks (like too few healthy and too many unhealthy foods) accounted for 6.6M CV deaths. 
  • CVD risk attributable to elevated systolic blood pressure was highest in Central Asia, Central Sub-Saharan Africa, and Eastern Europe.
  • CVD burden attributable to dietary risks was highest in Central Asia, Oceania, and Eastern Europe.
  • Central Asia had the highest age-standardized total CVD mortality at 517 deaths per 100k people, nearly 7 times higher than in Asia Pacific. 

On a brighter note, Australasia had the largest reduction (64.2%) in age-standardized CVD per 100k out of all other regions since 1990, driven by decreases in ischemic heart disease. 

The Takeaway

The ACC hopes to bring renewed attention to troubling trends related to the global CVD burden. The multi-year collaboration helps move the field forward by not only tracking CV risk and disease but also gauging whether interventions are actually effective. 

You might also like

Electrophysiology August 21, 2025

Conduction-System Pacing Succeeds at Treating AV Block August 21, 2025

Conduction-system pacing could be poised to reshape standard care for atrioventricular (AV) block patients after the randomized CSPACE trial demonstrated its significant benefits over traditional right ventricular septal pacing. Taking a closer look at CSP’s potential, the CSPACE trial enrolled 202 patients with AV block at two Australian hospitals, randomizing them to conduction-system pacing or […]

Cardiology Pharmaceuticals August 18, 2025

Rivaroxaban Monotherapy Could Be Better for CAD + AFib August 18, 2025

New analysis from the AFIRE trial suggests rivaroxaban monotherapy might be emerging as a preferred antithrombotic strategy for patients with AFib and stable coronary artery disease, especially in older age groups. The Post Hoc AFIRE Analysis examined 2,215 Japanese patients with AFib and stable CAD, stratifying them into four age groups (<70, 70-74, 75-79, and […]

Surgeries & Interventions August 14, 2025

TEER Could Save Lives in AFMR Patients August 14, 2025

Shedding light on a new treatment for an understudied condition, data published in EHJ suggests that transcatheter edge-to-edge repair (TEER) delivers significant survival advantages in patients with atrial functional mitral regurgitation (FMR). The new OCEAN-Mitral/REVEAL-AFMR Analysis compared 441 TEER-treated patients against 640 medically managed controls with moderate or severe atrial FMR, stating a solid case […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!